[Somatostatin receptor PET/CT (SSTR-PET/CT)].
C BoyT PoeppelJ KotzerkeB J KrauseH AmthauerR P BaumI BuchmannS EzziddinDagmar FuhrerM GabrielT KuwertH LahnerT LauensteinH R MaeckeJ NagarajahF RöschK ScheidhauerM SchmidtM A WalterA BockischPublished in: Nuklearmedizin. Nuclear medicine (2018)
The present guideline is focused on quality assurance of somatostatin receptor PET/CT (SSTR-PET/CT) in oncology patients. The document has been developed by a multidisciplinary board of specialists providing consensus of definitions, prerequisites, methodology, operating procedures, assessment, and standardized reporting. In particular, imaging procedures for the two most commonly used radioligands of human SSTR, i. e. 68Ga-DOTATOC and 68Ga-DOTATATE are presented. Overall, SSTR-PET/CT requires close interdisciplinary communication and cooperation of referring and executing medical disciplines, taking into account existing guidelines and recommendations of the European and German medical societies, including the European Association of Nuclear Medicine (EANM), German Society for Endocrinology (DGE), German Society for Nuclear Medicine (DGN) and German Society for Radiology (DRG).
Keyphrases
- pet ct
- positron emission tomography
- clinical practice
- healthcare
- end stage renal disease
- ejection fraction
- endothelial cells
- newly diagnosed
- high resolution
- prognostic factors
- artificial intelligence
- patient reported outcomes
- binding protein
- machine learning
- adverse drug
- mass spectrometry
- induced pluripotent stem cells
- patient reported